A multi-center team of scientists have received funding from the National Cancer Institute to develop compounds that may lead to an entirely new treatment for Acute Myeloid Leukemia (AML). The grant, which will provide $1.58 million over three years, will support medicinal chemistry, molecular modeling, and biological testing to optimize small molecule CXCR4-receptor antagonists and…